FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ingolf Meineke

Research Profile

Physiology

Chemicals & Drugs

Procedures

Phenomena

Metabolic Clearance Rate

Concepts & Ideas

Genes & Molecular Sequences

Co-author Network

Publications

TOP 3
Mladen Tzvetkov; K Bokelmann; R Kaiser; Ingolf Meineke; A R Saadatmand; Jürgen Brockmöller
Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron.
Daniel Sehrt; Mladen Tzvetkov; Senol Gültepe; Ingolf Meineke; Jürgen Brockmöller
Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
Mladen Vassilev Tzvetkov; Ingolf Meineke; Daniel Sehrt; Stefan Viktor Vormfelde; Jürgen Brockmöller
Amelogenin-based sex identification as a strategy to control the identity of DNA samples in genetic association studies.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ingolf Meineke (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Mladen Tzvetkov; K Bokelmann; R Kaiser; Ingolf Meineke; A R Saadatmand; Jürgen Brockmöller
Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron.
The pharmacogenomics journal 2012;12(1):22-9.
2011: Daniel Sehrt; Mladen Tzvetkov; Senol Gültepe; Ingolf Meineke; Jürgen Brockmöller
Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
Pharmacogenomics 2011;12(6):783-95.
2010: Mladen Vassilev Tzvetkov; Ingolf Meineke; Daniel Sehrt; Stefan Viktor Vormfelde; Jürgen Brockmöller
Amelogenin-based sex identification as a strategy to control the identity of DNA samples in genetic association studies.
Pharmacogenomics 2010;11(3):449-57.
2009: Mladen Tzvetkov; Stefan Viktor Vormfelde; D Balen; Ingolf Meineke; T Schmidt; Daniel Sehrt; I Sabolić; H Koepsell; Jürgen Brockmöller
The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.
Clinical pharmacology and therapeutics 2009;86(3):299-306.
2009: Stefan Viktor Vormfelde; Jürgen Brockmöller; S Bauer; P Herchenhein; J Kuon; Ingolf Meineke; Ivar Roots; Julia Kirchheiner
Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers.
Clinical pharmacology and therapeutics 2009;86(1):54-61.
2009: C Sachse-Seeboth; J Pfeil; Daniel Sehrt; Ingolf Meineke; Mladen Tzvetkov; E Bruns; Wolfgang Poser; Stefan Viktor Vormfelde; Jürgen Brockmöller
Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9.
Clinical pharmacology and therapeutics 2009;85(3):273-6.
2008: A Kühne; O Sezer; U Heider; Ingolf Meineke; S Muhlke; W Niere; T Overbeck; Karin Hohloch; Lorenz Trümper; Jürgen Brockmöller; Rolf Kaiser
Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects.
Clinical pharmacology and therapeutics 2008;83(5):749-57.
2008: Julia Kirchheiner; Ingolf Meineke; Uwe Fuhr; Cristina Rodríguez-Antona; Elena Lebedeva; Jürgen Brockmöller
Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids.
Pharmacogenomics 2008;9(3):277-88.
2007: Ingolf Meineke; Jürgen Brockmöller
Simulation of complex pharmacokinetic models in Microsoft Excel.
Computer methods and programs in biomedicine 2007;88(3):239-45.
2007: Stefan Viktor Vormfelde; Daniel Sehrt; Mohammad R Toliat; Markus Schirmer; Ingolf Meineke; Mladen Tzvetkov; Peter Nürnberg; Jürgen Brockmöller
Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs.
Clinical pharmacology and therapeutics 2007;82(3):300-9.
2007: Stefan Viktor Vormfelde; Markus Schirmer; Mohammad R Toliat; Ingolf Meineke; Julia Kirchheiner; Peter Nürnberg; Jürgen Brockmöller
Genetic variation at the CYP2C locus and its association with torsemide biotransformation.
The pharmacogenomics journal 2007;7(3):200-11.
2007: Jürgen Brockmöller; Ingolf Meineke; Julia Kirchheiner
Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects.
Clinical pharmacology and therapeutics 2007;81(5):699-707.
2007: Johannes Kornhuber; Evelin M Kennepohl; Stefan Bleich; Jens Wiltfang; Thomas Kraus; Udo Reulbach; Ingolf Meineke
Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach.
Clinical pharmacokinetics 2007;46(7):599-612.
2006: Julia Kirchheiner; Soju Thomas; Steffen Bauer; Dorota Tomalik-Scharte; Ursula Hering; Oxana Doroshyenko; Alexander Jetter; Simone Stehle; Martina Tsahuridu; Ingolf Meineke; Jürgen Brockmöller; Uwe Fuhr
Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.
Clinical pharmacology and therapeutics 2006;80(6):657-67.
2006: Ingolf Meineke; Hannelore Steinmetz; Julia Kirchheiner; Jürgen Brockmöller
Therapeutic drug monitoring of mirtazapine, desmethylmirtazapine, 8-hydroxymirtazapine, and mirtazapine-N-oxide by enantioselective HPLC with fluorescence detection.
Therapeutic drug monitoring 2006;28(6):760-5.
2006: Johannes Kornhuber; Peter Riederer; Stefan Bleich; Jens Wiltfang; Thomas Kraus; Ingolf Meineke
Pharmacokinetic characterization of amantadine in human brain tissue.
Therapeutic drug monitoring 2006;28(5):693-5.
2006: Stefan Viktor Vormfelde; Markus Schirmer; Yohannes Hagos; Mohammad R Toliat; Sabine Engelhardt; Ingolf Meineke; Gerhard Burckhardt; Peter Nürnberg; Jürgen Brockmöller
Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters.
British journal of clinical pharmacology 2006;62(3):323-35.
2006: Landry K Kamdem; Ingolf Meineke; Ute Gödtel-Armbrust; Jürgen Brockmöller; Leszek Wojnowski
Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B1.
Chemical research in toxicology 2006;19(4):577-86.
2006: Johannes Kornhuber; Harald Weigmann; J Röhrich; Jens Wiltfang; Stefan Bleich; Ingolf Meineke; Robert Zöchling; Sebastian Härtter; Peter Riederer; Christoph Hiemke
Region specific distribution of levomepromazine in the human brain.
Journal of neural transmission (Vienna, Austria : 1996) 2006;113(3):387-97.
2006: Sabine Engelhardt; Ingolf Meineke; Jürgen Brockmöller
Improved solid-phase extraction and HPLC measurement of torasemide and its important metabolites.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006;831(1-2):31-5.
2005: Julia Kirchheiner; Hanns-Benjamin Henckel; Leonora Franke; Ingolf Meineke; Mladen Tzvetkov; Ralf Uebelhack; Ivar Roots; Jürgen Brockmöller
Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets.
Pharmacogenetics and genomics 2005;15(8):579-87.
2004: Stefan Viktor Vormfelde; Sabine Engelhardt; Alexandra Zirk; Ingolf Meineke; Franziska Tuchen; Julia Kirchheiner; Jürgen Brockmöller
CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.
Clinical pharmacology and therapeutics 2004;76(6):557-66.
2004: Julia Kirchheiner; Hanns-Benjamin Henckel; Ingolf Meineke; Ivar Roots; Jürgen Brockmöller
Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers.
Journal of clinical psychopharmacology 2004;24(6):647-52.
2004: Julia Kirchheiner; Claudia Heesch; Steffen Bauer; Christian Meisel; Angela Seringer; Mark Goldammer; Mladen Tzvetkov; Ingolf Meineke; Ivar Roots; Jürgen Brockmöller
Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
Clinical pharmacology and therapeutics 2004;76(4):302-12.
2004: Landry K Kamdem; Ingolf Meineke; Ina Koch; Uli Zanger; Jürgen Brockmöller; Leszek Wojnowski
Limited contribution of CYP3A5 to the hepatic 6beta-hydroxylation of testosterone.
Naunyn-Schmiedeberg's archives of pharmacology 2004;370(1):71-7.
2004: Ingolf Meineke; Iris Kress; Wolfgang Poser; Eckart Rüther; Jürgen Brockmöller
Therapeutic drug monitoring of mirtazapine and its metabolite desmethylmirtazapine by HPLC with fluorescence detection.
Therapeutic drug monitoring 2004;26(3):277-83.
2004: Julia Kirchheiner; Ingolf Meineke; Göran Müller; Steffen Bauer; Wolfgang Rohde; Christian Meisel; Ivar Roots; Jürgen Brockmöller
Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.
Clinical pharmacokinetics 2004;43(4):267-78.
2003: Julia Kirchheiner; Johanna Sasse; Ingolf Meineke; Ivar Roots; Jürgen Brockmöller
Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity.
Pharmacogenetics 2003;13(12):721-8.
2003: Julia Kirchheiner; Gunnar Müller; Ingolf Meineke; Klaus-Dieter Wernecke; Ivar Roots; Jürgen Brockmöller
Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics.
Journal of clinical psychopharmacology 2003;23(5):459-66.
2003: Julia Kirchheiner; Christian Klein; Ingolf Meineke; Johanna Sasse; Uli Zanger; Thomas E Mürdter; Ivar Roots; Jürgen Brockmöller
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.
Pharmacogenetics 2003;13(10):619-26.
2003: Julia Kirchheiner; Dirk Kudlicz; Christian Meisel; Steffen Bauer; Ingolf Meineke; Ivar Roots; Jürgen Brockmöller
Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
Clinical pharmacology and therapeutics 2003;74(2):186-94.
2003: Julia Kirchheiner; Ingolf Meineke; Nadine Steinbach; Christian Meisel; Ivar Roots; Jürgen Brockmöller
Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans.
British journal of clinical pharmacology 2003;55(1):51-61.
2003: Ingolf Meineke; Dietrich Türck
Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients.
British journal of clinical pharmacology 2003;55(1):32-8.
2002: Ingolf Meineke; Stefan Freudenthaler; ute hofmann; Elke Schaeffeler; Gerd Mikus; Matthias Schwab; Hilmar W Prange; Christoph H Gleiter; Jürgen Brockmöller
Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine.
British journal of clinical pharmacology 2002;54(6):592-603.
2002: Julia Kirchheiner; Ingolf Meineke; Gunnar Müller; Ivar Roots; Jürgen Brockmöller
Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.
Pharmacogenetics 2002;12(7):571-80.
2002: Julia Kirchheiner; Ingolf Meineke; Georg Freytag; Christian Meisel; Ivar Roots; Jürgen Brockmöller
Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.
Clinical pharmacology and therapeutics 2002;72(1):62-75.
2002: M Meyer-Barner; Ingolf Meineke; KH Schreeb; Christoph H Gleiter
Pharmacokinetics of doxepin and desmethyldoxepin: an evaluation with the population approach.
European journal of clinical pharmacology 2002;58(4):253-7.
2002: Ingolf Meineke; Hannelore Steinmetz; Skaidrit Kramer; Christoph H Gleiter
Determination of fenoterol in human plasma by HPLC with fluorescence detection after derivatization.
Journal of pharmaceutical and biomedical analysis 2002;29(1-2):147-52.
2002: Julia Kirchheiner; Jürgen Brockmöller; Ingolf Meineke; Steffen Bauer; Wolfgang Rohde; Christian Meisel; Ivar Roots
Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
Clinical pharmacology and therapeutics 2002;71(4):286-96.
2002: Julia Kirchheiner; Steffen Bauer; Ingolf Meineke; Wolfgang Rohde; Verena Prang; Christian Meisel; Ivar Roots; Jürgen Brockmöller
Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.
Pharmacogenetics 2002;12(2):101-9.
2000: Ingolf Meineke
An add-in implementation of the RESAMPLING syntax under Microsoft EXCEL.
Computer methods and programs in biomedicine 2000;63(2):99-104.
2000: Jürgen Pilz; Ingolf Meineke; Christoph H Gleiter
Measurement of free and bound malondialdehyde in plasma by high-performance liquid chromatography as the 2,4-dinitrophenylhydrazine derivative.
Journal of chromatography. B, Biomedical sciences and applications 2000;742(2):315-25.
1999: Johannes Kornhuber; A Schultz; Jens Wiltfang; Ingolf Meineke; C H Gleiter; Robert Zöchling; KW Boissl; Friedrich Leblhuber; Peter Riederer
Persistence of haloperidol in human brain tissue.
The American journal of psychiatry 1999;156(6):885-90.
1998: Ingolf Meineke; J Eisele; H Certa; Ursula Gundert-Remy
Modelling of residual variability in toxicokinetic studies with sparse sampling: the case of tetrahydronaphthalene.
Archives of toxicology 1998;72(12):807-10.
1998: Stefan Freudenthaler; Ingolf Meineke; KH Schreeb; E Boakye; Ursula Gundert-Remy; Christoph H Gleiter
Influence of urine pH and urinary flow on the renal excretion of memantine.
British journal of clinical pharmacology 1998;46(6):541-6.
1998: Ingolf Meineke; Christoph H Gleiter
Assessment of drug accumulation in the evaluation of pharmacokinetic data.
Journal of clinical pharmacology 1998;38(8):680-4.
1998: Ingolf Meineke; Herbert Desel; Regine Kahl; Georg F Kahl; Ursula Gundert-Remy
Determination of 2-hydroxyphenylacetic acid (2HPAA) in urine after oral and parenteral administration of coumarin by gas-liquid chromatography with flame-ionization detection.
Journal of pharmaceutical and biomedical analysis 1998;17(3):487-92.
1998: Ingolf Meineke; KH Schreeb; I Kress; Ursula Gundert-Remy
Routine measurement of fluoxetine and norfluoxetine by high-performance liquid chromatography with ultraviolet detection in patients under concomitant treatment with tricyclic antidepressants.
Therapeutic drug monitoring 1998;20(1):14-9.
1997: Ingolf Meineke; W Schmidt; M Nottrott; T Schröder; Gerhard Hellige; Ursula Gundert-Remy
Modelling of non-linear pharmacokinetics in sheep after short-term infusion of cardiotoxic doses of imipramine.
Pharmacology & toxicology 1997;80(6):266-71.
1997: Ingolf Meineke; H Feltkamp; A Högemann; Ursula Gundert-Remy
Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension--a population analysis.
European journal of clinical pharmacology 1997;53(3-4):221-8.
1997: Stefan Viktor Vormfelde; A Bitsch; Ingolf Meineke; Ursula Gundert-Remy; Christoph H Gleiter
Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6?
European journal of clinical pharmacology 1997;52(5):387-90.
1996: S V Löser; J Meyer; Stefan Freudenthaler; M Sattler; C Desel; Ingolf Meineke; Ursula Gundert-Remy
Morphine-6-O-beta-D-glucuronide but not morphine-3-O-beta-D-glucuronide binds to mu-, delta- and kappa- specific opioid binding sites in cerebral membranes.
Naunyn-Schmiedeberg's archives of pharmacology 1996;354(2):192-7.
1996: Thomas Bouillon; Ingolf Meineke; Ruediger E Port; R Hildebrandt; K Günther; Ursula Gundert-Remy
Concentration-effect relationship of the positive chronotropic and hypokalaemic effects of fenoterol in healthy women of childbearing age.
European journal of clinical pharmacology 1996;51(2):153-60.
1995: Ingolf Meineke; S Rohde; Ursula Gundert-Remy
An inexpensive and sensitive method for the determination of quinidine in plasma by high-performance liquid chromatography with ultraviolet detection.
Therapeutic drug monitoring 1995;17(1):75-8.
1993: Ingolf Meineke; C De Mey; R Eggers; F E Bauer
Evaluation of the 13CO2 kinetics in humans after oral application of sodium bicarbonate as a model for breath testing.
European journal of clinical investigation 1993;23(2):91-6.